Long-term, high-dose opioid prescription for chronic non-cancer pain in primary care
Research output: Contribution to journal › Article › peer-review
Standard Standard
In: BJGP open, Vol. 6, No. 4, BJGPO.2021.0217., 12.2022.
Research output: Contribution to journal › Article › peer-review
HarvardHarvard
APA
CBE
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - Long-term, high-dose opioid prescription for chronic non-cancer pain in primary care
AU - Bailey, John
AU - Gill, Simon
AU - Poole, Rob
PY - 2022/12
Y1 - 2022/12
N2 - Background: Opioid prescriptions for chronic pain have risen sharply over the last 25 years; harms associated with these drugs are related to dose and length of use.Aim: The main aim of this study was to identify patients prescribed long-term, high-dose (LTHD) opioids in the community and to assess the prevalence of such use.Design & setting: An observational study of opioid prescribing in two demographically dissimilar GP practices in North Wales, UK.Method: Details of opioid prescriptions were collected for 22 841 patients, of whom 1488 (6.5%) were being prescribed opioids on the census date. Exhaustive examination of the data identified all patients who were prescribed oral morphine equivalent doses of ≥120 mg/day for ≥1 year.Results: All these patients were being prescribed ≥120 mg/day, as a single drug, morphine, oxycodone, fentanyl, or buprenorphine, irrespective of opioid polypharmacy. Across both practices, 1.71/1000 patients were identified as LTHD users of opioid medication for chronic non-cancer pain (CNCP). Prevalence was similar in the two practices. Repetition of the process until January 2021 showed no change in the pattern.Conclusion: This study offers confirmation that a significant group of patients are prescribed long-term opioid medication for chronic pain at doses that are unlikely to be effective in reducing pain, but are likely to have harmful consequences. The findings offer a simple, reliable, and practical method ofdata extraction to identify these patients individually from routinely collected prescribing data, which will help in monitoring and treating individuals and establishing the problem prevalence.
AB - Background: Opioid prescriptions for chronic pain have risen sharply over the last 25 years; harms associated with these drugs are related to dose and length of use.Aim: The main aim of this study was to identify patients prescribed long-term, high-dose (LTHD) opioids in the community and to assess the prevalence of such use.Design & setting: An observational study of opioid prescribing in two demographically dissimilar GP practices in North Wales, UK.Method: Details of opioid prescriptions were collected for 22 841 patients, of whom 1488 (6.5%) were being prescribed opioids on the census date. Exhaustive examination of the data identified all patients who were prescribed oral morphine equivalent doses of ≥120 mg/day for ≥1 year.Results: All these patients were being prescribed ≥120 mg/day, as a single drug, morphine, oxycodone, fentanyl, or buprenorphine, irrespective of opioid polypharmacy. Across both practices, 1.71/1000 patients were identified as LTHD users of opioid medication for chronic non-cancer pain (CNCP). Prevalence was similar in the two practices. Repetition of the process until January 2021 showed no change in the pattern.Conclusion: This study offers confirmation that a significant group of patients are prescribed long-term opioid medication for chronic pain at doses that are unlikely to be effective in reducing pain, but are likely to have harmful consequences. The findings offer a simple, reliable, and practical method ofdata extraction to identify these patients individually from routinely collected prescribing data, which will help in monitoring and treating individuals and establishing the problem prevalence.
KW - Opioid analgesics
KW - chronic pain
KW - Drug prescribing
KW - primary care
KW - General practice
U2 - DOI:10.3399/BJGPO.2021.0217
DO - DOI:10.3399/BJGPO.2021.0217
M3 - Article
VL - 6
JO - BJGP open
JF - BJGP open
SN - 2398-3795
IS - 4
M1 - BJGPO.2021.0217.
ER -